376 related articles for article (PubMed ID: 25596071)
1. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
[TBL] [Abstract][Full Text] [Related]
2. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
[TBL] [Abstract][Full Text] [Related]
5. Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients.
Yoshikawa S; Yoshio S; Yoshida Y; Tsutsui Y; Kawai H; Yamazoe T; Mori T; Osawa Y; Sugiyama M; Iwamoto M; Watashi K; Kawaguchi T; Akita T; Tanaka J; Kikuchi Y; Mizokami M; Oka S; Kanto T; Gatanaga H
J Infect Dis; 2021 Jun; 223(12):2080-2089. PubMed ID: 33073291
[TBL] [Abstract][Full Text] [Related]
6. [A case of hepatitis B virus/human immunodeficiency virus coinfection in a patient who achived hepatitis B surface antigen seroclearance after interferon therapy followed by antiretroviral therapy without developing immune reconstitution inflammatory syndrome].
Mitsumoto F; Murata M; Ikezaki H; Ogawa E; Taniai H; Toyoda K; Otaguro S; Kainuma M; Okada K; Furusyo N; Hayashi J
Kansenshogaku Zasshi; 2012 Nov; 86(6):763-7. PubMed ID: 23367852
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
[TBL] [Abstract][Full Text] [Related]
8. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
9. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
[TBL] [Abstract][Full Text] [Related]
11. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
[TBL] [Abstract][Full Text] [Related]
13. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.
Arendt E; Jaroszewicz J; Rockstroh J; Meyer-Olson D; Zacher BJ; Mederacke I; Manns MP; Wedemeyer H; Cornberg M; Wursthorn K
Viral Immunol; 2012 Dec; 25(6):442-7. PubMed ID: 23131018
[TBL] [Abstract][Full Text] [Related]
14. [Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].
Zhang RF; Liu L; Zheng YF; Shen YZ; Chen J; Gu SM; Wang JR; Lu HZ
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):189-91. PubMed ID: 23967739
[TBL] [Abstract][Full Text] [Related]
15. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
[TBL] [Abstract][Full Text] [Related]
16. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French M; Ruxrungtham K; Lewin SR
J Infect Dis; 2009 Apr; 199(7):974-81. PubMed ID: 19231993
[TBL] [Abstract][Full Text] [Related]
17. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
18. Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
Li Y; Xie J; Wang H; Han Y; Wang N; Thio CL; Li T
Antivir Ther; 2017; 22(6):523-527. PubMed ID: 28195558
[TBL] [Abstract][Full Text] [Related]
19. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
20. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]